

## البحث الخامس

Olfat G. Shaker, Rania H. Mahmoud , Omayma O. Abdelaleem, Enas G. Ibrahim, Abdelrahmaan A. Mohamed, Othman M. Zaki, Noha K. Abdelghaffar, Tarek I. Ahmed, <b>Nada F. Hemeda</b> , Naglaa A. Ahmed and Dina F. Mansour (2019). LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis. Bioscience Reports, 39 (1): BSR20181335 <a href="https://doi.org/10.1042/BSR20181335">https://doi.org/10.1042/BSR20181335</a> .	البحث الخامس
--	--------------

<b>Title</b>	<b>LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis.</b>
<b>Date</b>	<b>2019</b>

### ABSTRACT

Long non-coding RNAs (lncRNAs) play an important role in gene regulation and show greater tissue specificity and complexity of biological functions. There is on-going research in their contribution in autoimmune diseases like multiple sclerosis (MS). Our study aimed at the evaluation of serum levels of lncRNAs, MALAT1 and lnc-DC in MS patients and the investigation of the association between these lncRNAs and the disease activity. Serum from 45 MS patients and 45 healthy controls was separated. MALAT1 and lnc-DC expression levels were assayed by qRT-PCR. MALAT1 and lnc-DC were significantly increased in MS patients ( $P=0.004$  and  $P=0.006$ , respectively) in comparison with controls. There was a significant increase in expression of MALAT1 in secondary progressive MS (SPMS) subgroup compared with controls ( $P<0.0001$ ); however, significant elevation of lnc-DC was demonstrated in relapsing remitting MS (RRMS) subtype ( $P=0.003$ ) compared with normal controls.

A positive association between the expression levels of MALAT1 and lnc-DC ( $r = 0.513$ ,  $P < 0.0001$ ) in MS patients was detected. Moreover, positive correlation was observed between MALAT1 and lnc-DC in RRMS ( $r = 0.569$ ,  $P = 0.001$ ). Serum levels of MALAT1 and lnc-DC may serve as potential novel molecular biomarkers for MS diagnosis and may provide a new direction for its treatment.